In the realm of mental health innovation, Compass Pathways plc (CMPS) is recalibrating its clinical and regulatory trajectory with a decisive acceleration in its commercialization timeline.
The company recently announced a 9-12 month acceleration in its commercialization readiness plans for COMP360, its investigational psilocybin therapy for treatment-resistant depression (TRD). This strategic pivot follows a completed Phase 3 trial (COMP006) enrollment and favorable FDA feedback on submission strategy, including the potential for rolling NDA review.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.